Corrigendum: The genomic landscape of juvenile myelomonocytic leukemia.
Elliot Stieglitz,Amaro Taylor-Weiner,Tiffany Y. Chang,Laura C. Gelston,Yong Dong Wang,Tali Mazor,Emilio Esquivel,Ariel Yu,Sara Seepo,Scott R. Olsen,Mara Rosenberg,Sophie Archambeault,Ghada Abusin,Kyle Beckman,Patrick A. Brown,Michael Briones,Benjamin Carcamo,Todd M. Cooper,Gary V. Dahl,Peter D. Emanuel,Mark Fluchel,Rakesh K. Goyal,Robert J. Hayashi,Johann Hitzler,Christopher Hugge,Y. Lucy Liu,Yoav H. Messinger,Donald H. Mahoney,Philip M. Monteleone,Eneida R. Nemecek,Philip A. Roehrs,Reuven J. Schore,Kimo C. Stine,Clifford M. Takemoto,Jeffrey A. Toretsky,Joseph F. Costello,Adam B. Olshen,Chip Stewart,Yongjin Li,Jing Ma,Robert B. Gerbing,Todd A. Alonzo,Gad Getz,Tanja A. Gruber,Todd R. Golub,Kimberly Stegmaier,Mignon L. Loh +46 more
Reads0
Chats0
TLDR
In this paper, two patients were stated on page 5 to have been excluded owing to insufficient follow-up data, but two additional patients were excluded due to the presence of Noonan syndrome.Abstract:
Nat. Genet. 47, 1326–1333 (2015); published online 12 October 2015; corrected after print 7 December 2015 In the version of this article initially published, two patients were stated on page 5 to have been excluded owing to insufficient follow-up data. These patients were included in the final analysis, but two additional patients were excluded owing to the presence of Noonan syndrome.read more
Citations
More filters
Journal ArticleDOI
Modeling cancer using patient-derived induced pluripotent stem cells to understand development of childhood malignancies
TL;DR: Stem cell properties, including self-renewal and their potential to virtually differentiate into any cell type, emphasize their importance as a translational tool for modeling disorders that so far have been limited by the unavailability of primary cell lines, animal models, or inaccessible human materials.
Journal ArticleDOI
Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review
TL;DR: Protein arginine methyltransferase 5 (PRMT5) inhibitors are a new class of antineoplastic agents showing promising preliminary clinical efficacy as discussed by the authors , targeting an enzyme involved in a wide array of cellular and transcriptional pro-oncogenic processes, this class offers multifaceted tumorsuppressive effects.
Journal ArticleDOI
Clinical Impact of Genomic Information in Pediatric Leukemia.
TL;DR: This review summarizes genetic and genomic techniques used in clinical laboratories to support management of pediatric leukemia, highlighting technical, biological, and clinical advances and providing a future perspective on clinical genomics and precision medicine.
References
More filters
Journal ArticleDOI
The genomic landscape of juvenile myelomonocytic leukemia.
Elliot Stieglitz,Amaro Taylor-Weiner,Tiffany Y. Chang,Laura C. Gelston,Yong Dong Wang,Tali Mazor,Emilio Esquivel,Ariel Yu,Sara Seepo,Scott R. Olsen,Mara Rosenberg,Sophie Archambeault,Ghada Abusin,Kyle Beckman,Patrick A. Brown,Michael Briones,Benjamin Carcamo,Todd Cooper,Gary V. Dahl,Peter D. Emanuel,Mark Fluchel,Rakesh K. Goyal,Robert J. Hayashi,Johann Hitzler,Christopher Hugge,Y. Lucy Liu,Yoav Messinger,Donald H. Mahoney,Philip M. Monteleone,Eneida R. Nemecek,Philip A. Roehrs,Reuven J. Schore,Kimo C. Stine,Clifford M. Takemoto,Jeffrey A. Toretsky,Joseph F. Costello,Adam B. Olshen,Chip Stewart,Yongjin Li,Jing Ma,Robert B. Gerbing,Todd A. Alonzo,Gad Getz,Gad Getz,Tanja A. Gruber,Todd R. Golub,Todd R. Golub,Kimberly Stegmaier,Kimberly Stegmaier,Mignon L. Loh +49 more
TL;DR: Genomically characterize serial samples from patients at diagnosis through relapse and transformation to acute myeloid leukemia to expand knowledge of the mutational spectrum in JMML and identified recurrent mutations in genes involved in signal transduction, splicing, Polycomb repressive complex 2 (PRC2) and transcription.